A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)
Recruiting · Phase 1 · NCT06888193
Conditions: Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Axial Spondyloarthritis, Hidradenitis Suppurativa
At a glance
- Research payments reported, 2025
- $60,729
- U.S. investigators named
- 3
- Sites paid
- 4
- Planned or actual enrollment
- 20
About the trial
- Sponsor
- UCB Biopharma SRL
- Tested
- Bimekizumab (drug)
- Dates
- Started 2025-11-05; completion 2027-12-31
- Results posted
- Not yet
Primary purpose of the study is to assess the concentration of bimekizumab in mature human breast milk.
From ClinicalTrials.gov, last updated 2026-09-18. Full record, eligibility and contacts (opens in a new tab)
Industry funding
UCB SA reported $60,729 in research payments for this study in 2025 (5 payments).
Products named: Bimzelx
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Paul S. Yamauchi, M.D., PHD Dermatology · Santa Monica, CA
- Olga Kromo, M.D. Rheumatology · South Miami, FL
- Megan Clowse Rheumatology · Durham, NC
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Duke University Medical Center $38,719
- Miami Clinical Research $16,500
- Dermatology Institute and Skin Care Center $2,789
- Qps Miami Research Associates $2,720
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.